Cargando…
Satralizumab for neuromyelitis optica spectrum disorder
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
NPS MedicineWise
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882450/ https://www.ncbi.nlm.nih.gov/pubmed/35233140 http://dx.doi.org/10.18773/austprescr.2021.065 |
Ejemplares similares
-
Complete Relief of Painful Tonic Seizures in Neuromyelitis Optica Spectrum Disorder by Satralizumab Treatment
por: Uzawa, Akiyuki, et al.
Publicado: (2022) -
Eculizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Frampton, James E.
Publicado: (2020) -
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
por: Nie, Tina, et al.
Publicado: (2022) -
Satralizumab as an add-on treatment in refractory pediatric AQP4-antibody-positive neuromyelitis optica spectrum disorder: a case report
por: Li, Xiaojing, et al.
Publicado: (2023) -
Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar
por: Kleiter, Ingo, et al.
Publicado: (2022)